マルチプレックスアッセイの世界市場：市場規模・シェア分析 (製品別・種類別・技術別)、産業需要の予測 (～2030年)

世界のマルチプレックスアッセイ市場は、9.0%のCAGRで成長し、2023年には39億1,800万米ドル、2030年には71億350万米ドルに達します。

この背景には、慢性疾患や感染症の急増があります。さらに、研究者・患者・医療提供者の出費を減らすために、研究・臨床診断において開発された分析プラットフォームに対する需要が高まっていることも主な要因です。

セグメント別の分析

製品別に見ると、2023年には消耗品カテゴリーが45%のシェアで業界をリードしました。これは、診断検査数の増加とライフサイエンス企業による研究活動の高まりによるものです。

技術別では、マルチプレックス・リアルタイムPCRのカテゴリーが、今後数年間で9.4%と最も速い速度で進歩すると思われます。これはPCRシステムの様々なバリエーションが迅速に発売されるためです。

アジア太平洋が急成長地域となる

アジア太平洋が最も速い速度で進歩しているのは、病院数の増加、この産業への投資額の上昇、そして整備された医療インフラへの高い要求のためです。また、中国は域内で最も急成長している国です。

北米は2023年に55%のシェアを占め、この業界で最大のシェアを占め、今後数年で大きく前進すると思われます。これは、新薬や診断ソリューションを開発するための製薬会社やバイオテクノロジー企業による研究開発活動が活発化しているためです。

当レポートでは、世界のマルチプレックスアッセイの市場について分析し、市場の基本構造・最新情勢や主な促進・抑制要因、世界全体および地域別・主要国の市場規模の動向見通し (金額ベース、2017～2030年)、製品別・種類別・技術別の詳細動向、現在の市場競争の状況、主要企業のプロファイルなどを調査しております。

目次

第1章 調査範囲

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場指標

第5章 業界の展望

• 市場力学
  • 動向
  • 促進要因
  • 抑制要因/課題
  • 促進要因/抑制要因の影響分析
• 新型コロナウイルス感染症 (COVID-19) の影響
• ポーターのファイブフォース分析

第6章 世界市場

• 概要
• 市場収益：製品別 (2017～2030年)
• 市場収益：種類別 (2017～2030年)
• 市場収益：技術別 (2017～2030年)
• 市場収益：地域別 (2017～2030年)

第7章 北米市場

• 概要
• 市場収益：製品別 (2017～2030年)
• 市場収益：種類別 (2017～2030年)
• 市場収益：技術別 (2017～2030年)
• 市場収益：国別 (2017～2030年)

第8章 欧州市場

第9章 アジア太平洋市場

第10章 ラテンアメリカ市場

第11章 中東・アフリカ (MEA) 市場

第12章 米国市場

• 概要
• 市場収益：製品別 (2017～2030年)
• 市場収益：種類別 (2017～2030年)
• 市場収益：技術別 (2017～2030年)

第13章 カナダ市場

第14章 ドイツ市場

第15章 フランス市場

第16章 英国市場

第17章 イタリア市場

第18章 スペイン市場

第19章 日本市場

第20章 中国市場

第21章 インド市場

第22章 オーストラリア市場

第23章 韓国市場

第24章 ブラジル市場

第25章 メキシコ市場

第26章 サウジアラビア市場

第27章 南アフリカ市場

第28章 アラブ首長国連邦 (UAE) 市場

第29章 競合情勢

• 市場参入企業とその提供製品/サービスの一覧
• 主要企業の競合ベンチマーク
• 主要企業の製品ベンチマーク
• 最近の戦略展開状況

第30章 企業プロファイル

• Thermo Fisher Scientific Inc.
• Illumina Inc.
• Bio-Rad Laboratories Inc.
• Qiagen N.V.
• Abcam plc
• Becton, Dickinson and Company
• Merck KGaA
• Agilent Technologies Inc.
• Meso Scale Diagnostics LLC

第31章 付録

The multiplex assays market was USD 3,918.0 million in 2023, which will reach USD 7,103.5 million, powering at a 9.0% CAGR, by 2030.

This is because of the surging incidence of chronic ailments as well as infectious diseases. Furthermore, the rising demand for developed analytical platforms in research and clinical diagnostics, to decrease the expenses for researchers, patients, and healthcare providers is also a key contributor.

According to the World Health Organization, chronic diseases including cancer, cardiovascular diseases, respiratory illnesses, and diabetes, will account for 86% of the 90 million deaths annually by around 2050, a significant increase of 90% since 2019.

Moreover, there were an estimated 249 million cases of malaria and 608,000 deaths from this disease in 85 nations in 2022. In addition, in the same year, there were around 39 million individuals with HIV globally. Of these, 1.5 million were children (below 15 years of age), and 37.5 million were adults. Additionally, 53% were girls and women.

The COVID-19 pandemic has had a positive impact on the industry, by driving an enormous rise in research & development for the production of innovative solutions to detect coronavirus.

Furthermore, the surging elderly population and incidence of autoimmune ailments, cancer, and human immunodeficiency virus are likely to drive the industry growth during this decade.

Segmentation Insights

The consumables category, based on product, led the industry in 2023, with a 45% share. This is because of the increasing count of diagnostic tests and the rising research activities by life sciences businesses.

For example, in January 2023, Novo Nordisk, a pharmaceutical firm, declared a grant of USD 6 million for Durham Technical Community College.

The grant is to assist the latter's life sciences program and build a new 35,000-square-foot training center.

In 2023, the protein-based category, based on type, accounted for the largest share, of 50%, owing to the rising adoption of such products in proteomics studies. Furthermore, protein-based assays are extensively employed in research to classify the concentration of electrophoresis, cell biology, protein, and various other analytes.

The multiplex real-time PCR category, based on technology, is likely to advance at the fastest rate, of 9.4%, in the years to come. This can be ascribed to the swift launch of different variants of PCR systems.

APAC is Fastest-Growing Region

APAC is advancing at the fastest rate, because of the increasing number of hospitals, rising investment value in this industry, and high requirement for developed healthcare infrastructure. In addition, China is the fastest-growing nation in APAC.

North America was the largest contributor to the industry in 2023, with a 55% share, and it will advance significantly in the years to come. This is because of the increasing research & development activities by pharmaceutical and biotechnology firms to develop new drugs as well as diagnostic solutions.

Competition Analysis

Key players are highly focused on investments and innovations to develop panels and devices for the multiplexed detection of the virus. Also, businesses are engaging in partnerships to distribute immunometric assays.

Oxford Nanopore Technologies and 10x Genomics, in October 2022, announced a partnership to develop an efficient workflow for full-length transcript sequencing in a single read on the devices of Oxford Nanopore.

This partnership enables the integration of Oxford's Promethlon devices as well as sample preparation on 10x Genomics devices, along with selected consumables.

With the surging incidence of infectious and chronic diseases, the multiplex assays industry will grow continuously in the coming years.

Table of Contents

Chapter 1. Research Scope

• 1.1. Research Objectives
• 1.2. Market Definition
• 1.3. Analysis Period
• 1.4. Market Size Breakdown by Segments
  • 1.4.1. Market size breakdown, by product
  • 1.4.2. Market size breakdown, by type
  • 1.4.3. Market size breakdown, by technology
  • 1.4.4. Market size breakdown, by region
  • 1.4.5. Market size breakdown, by country
• 1.5. Market Data Reporting Unit
  • 1.5.1. Value
• 1.6. Key Stakeholders

Chapter 2. Research Methodology

• 2.1. Secondary Research
  • 2.1.1. Paid
  • 2.1.2. Unpaid
  • 2.1.3. P&S Intelligence database
• 2.2. Primary Research
• 2.3. Market Size Estimation
• 2.4. Data Triangulation
• 2.5. Currency Conversion Rates
• 2.6. Assumptions for the Study
• 2.7. Notes and Caveats

Chapter 3. Executive Summary

Chapter 4. Market Indicators

Chapter 5. Industry Outlook

• 5.1. Market Dynamics
  • 5.1.1. Trends
  • 5.1.2. Drivers
  • 5.1.3. Restraints/challenges
  • 5.1.4. Impact analysis of drivers/restraints
• 5.2. Impact of COVID-19
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Bargaining power of buyers
  • 5.3.2. Bargaining power of suppliers
  • 5.3.3. Threat of new entrants
  • 5.3.4. Intensity of rivalry
  • 5.3.5. Threat of substitutes

Chapter 6. Global Market

• 6.1. Overview
• 6.2. Market Revenue, by Product (2017-2030)
• 6.3. Market Revenue, by Type (2017-2030)
• 6.4. Market Revenue, by Technology (2017-2030)
• 6.5. Market Revenue, by Region (2017-2030)

Chapter 7. North America Market

• 7.1. Overview
• 7.2. Market Revenue, by Product (2017-2030)
• 7.3. Market Revenue, by Type (2017-2030)
• 7.4. Market Revenue, by Technology (2017-2030)
• 7.5. Market Revenue, by Country (2017-2030)

Chapter 8. Europe Market

• 8.1. Overview
• 8.2. Market Revenue, by Product (2017-2030)
• 8.3. Market Revenue, by Type (2017-2030)
• 8.4. Market Revenue, by Technology (2017-2030)
• 8.5. Market Revenue, by Country (2017-2030)

Chapter 9. APAC Market

• 9.1. Overview
• 9.2. Market Revenue, by Product (2017-2030)
• 9.3. Market Revenue, by Type (2017-2030)
• 9.4. Market Revenue, by Technology (2017-2030)
• 9.5. Market Revenue, by Country (2017-2030)

Chapter 10. LATAM Market

• 10.1. Overview
• 10.2. Market Revenue, by Product (2017-2030)
• 10.3. Market Revenue, by Type (2017-2030)
• 10.4. Market Revenue, by Technology (2017-2030)
• 10.5. Market Revenue, by Country (2017-2030)

Chapter 11. MEA Market

• 11.1. Overview
• 11.2. Market Revenue, by Product (2017-2030)
• 11.3. Market Revenue, by Type (2017-2030)
• 11.4. Market Revenue, by Technology (2017-2030)
• 11.5. Market Revenue, by Country (2017-2030)

Chapter 12. U.S. Market

• 12.1. Overview
• 12.2. Market Revenue, by Product (2017-2030)
• 12.3. Market Revenue, by Type (2017-2030)
• 12.4. Market Revenue, by Technology (2017-2030)

Chapter 13. Canada Market

• 13.1. Overview
• 13.2. Market Revenue, by Product (2017-2030)
• 13.3. Market Revenue, by Type (2017-2030)
• 13.4. Market Revenue, by Technology (2017-2030)

Chapter 14. Germany Market

• 14.1. Overview
• 14.2. Market Revenue, by Product (2017-2030)
• 14.3. Market Revenue, by Type (2017-2030)
• 14.4. Market Revenue, by Technology (2017-2030)

Chapter 15. France Market

• 15.1. Overview
• 15.2. Market Revenue, by Product (2017-2030)
• 15.3. Market Revenue, by Type (2017-2030)
• 15.4. Market Revenue, by Technology (2017-2030)

Chapter 16. U.K. Market

• 16.1. Overview
• 16.2. Market Revenue, by Product (2017-2030)
• 16.3. Market Revenue, by Type (2017-2030)
• 16.4. Market Revenue, by Technology (2017-2030)

Chapter 17. Italy Market

• 17.1. Overview
• 17.2. Market Revenue, by Product (2017-2030)
• 17.3. Market Revenue, by Type (2017-2030)
• 17.4. Market Revenue, by Technology (2017-2030)

Chapter 18. Spain Market

• 18.1. Overview
• 18.2. Market Revenue, by Product (2017-2030)
• 18.3. Market Revenue, by Type (2017-2030)
• 18.4. Market Revenue, by Technology (2017-2030)

Chapter 19. Japan Market

• 19.1. Overview
• 19.2. Market Revenue, by Product (2017-2030)
• 19.3. Market Revenue, by Type (2017-2030)
• 19.4. Market Revenue, by Technology (2017-2030)

Chapter 20. China Market

• 20.1. Overview
• 20.2. Market Revenue, by Product (2017-2030)
• 20.3. Market Revenue, by Type (2017-2030)
• 20.4. Market Revenue, by Technology (2017-2030)

Chapter 21. India Market

• 21.1. Overview
• 21.2. Market Revenue, by Product (2017-2030)
• 21.3. Market Revenue, by Type (2017-2030)
• 21.4. Market Revenue, by Technology (2017-2030)

Chapter 22. Australia Market

• 22.1. Overview
• 22.2. Market Revenue, by Product (2017-2030)
• 22.3. Market Revenue, by Type (2017-2030)
• 22.4. Market Revenue, by Technology (2017-2030)

Chapter 23. South Korea Market

• 23.1. Overview
• 23.2. Market Revenue, by Product (2017-2030)
• 23.3. Market Revenue, by Type (2017-2030)
• 23.4. Market Revenue, by Technology (2017-2030)

Chapter 24. Brazil Market

• 24.1. Overview
• 24.2. Market Revenue, by Product (2017-2030)
• 24.3. Market Revenue, by Type (2017-2030)
• 24.4. Market Revenue, by Technology (2017-2030)

Chapter 25. Mexico Market

• 25.1. Overview
• 25.2. Market Revenue, by Product (2017-2030)
• 25.3. Market Revenue, by Type (2017-2030)
• 25.4. Market Revenue, by Technology (2017-2030)

Chapter 26. Saudi Arabia Market

• 26.1. Overview
• 26.2. Market Revenue, by Product (2017-2030)
• 26.3. Market Revenue, by Type (2017-2030)
• 26.4. Market Revenue, by Technology (2017-2030)

Chapter 27. South Africa Market

• 27.1. Overview
• 27.2. Market Revenue, by Product (2017-2030)
• 27.3. Market Revenue, by Type (2017-2030)
• 27.4. Market Revenue, by Technology (2017-2030)

Chapter 28. U.A.E. Market

• 28.1. Overview
• 28.2. Market Revenue, by Product (2017-2030)
• 28.3. Market Revenue, by Type (2017-2030)
• 28.4. Market Revenue, by Technology (2017-2030)

Chapter 29. Competitive Landscape

• 29.1. List of Market Players and their Offerings
• 29.2. Competitive Benchmarking of Key Players
• 29.3. Product Benchmarking of Key Players
• 29.4. Recent Strategic Developments

Chapter 30. Company Profiles

• 30.1. Thermo Fisher Scientific Inc.
  • 30.1.1. Business overview
  • 30.1.2. Product and service offerings
  • 30.1.3. Key financial summary
• 30.2. Illumina Inc.
  • 30.2.1. Business overview
  • 30.2.2. Product and service offerings
  • 30.2.3. Key financial summary
• 30.3. Bio-Rad Laboratories Inc.
  • 30.3.1. Business overview
  • 30.3.2. Product and service offerings
  • 30.3.3. Key financial summary
• 30.4. Qiagen N.V.
  • 30.4.1. Business overview
  • 30.4.2. Product and service offerings
  • 30.4.3. Key financial summary
• 30.5. Abcam plc
  • 30.5.1. Business overview
  • 30.5.2. Product and service offerings
  • 30.5.3. Key financial summary
• 30.6. Becton, Dickinson and Company
  • 30.6.1. Business overview
  • 30.6.2. Product and service offerings
  • 30.6.3. Key financial summary
• 30.7. Merck KGaA
  • 30.7.1. Business overview
  • 30.7.2. Product and service offerings
  • 30.7.3. Key financial summary
• 30.8. Agilent Technologies Inc.
  • 30.8.1. Business overview
  • 30.8.2. Product and service offerings
  • 30.8.3. Key financial summary
• 30.9. Meso Scale Diagnostics LLC
  • 30.9.1. Business overview
  • 30.9.2. Product and service offerings
  • 30.9.3. Key financial summary

Chapter 31. Appendix

• 31.1. Abbreviations
• 31.2. Sources and References
• 31.3. Related Reports